A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

This phase I/II dose-escalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent ixazomib maintenance, in elderly, transplant-ineligible patients with newly diagnosed multiple myeloma. Primary phase I objectives were to determine the safety and recommen...

Descripción completa

Detalles Bibliográficos
Autores principales: San-Miguel, Jesús F., Echeveste Gutierrez, Maria-Asunción, Špicka, Ivan, Mateos, María-Victoria, Song, Kevin, Craig, Michael D., Bladé, Joan, Hájek, Roman, Chen, Christine, Di Bacco, Alessandra, Estevam, Jose, Gupta, Neeraj, Byrne, Catriona, Lu, Vickie, van de Velde, Helgi, Lonial, Sagar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119151/
https://www.ncbi.nlm.nih.gov/pubmed/29954932
http://dx.doi.org/10.3324/haematol.2017.185991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119151/
https://www.ncbi.nlm.nih.gov/pubmed/29954932
http://dx.doi.org/10.3324/haematol.2017.185991

Ejemplares similares